UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma

Frontiers in immunology, 2023-10, Vol.14, p.1261257-1261257

2023

Volltextzugriff (PDF)

CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix

BMC cancer, 2021-07, Vol.21 (1), p.1-765, Article 765

2021

Volltextzugriff (PDF)

DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images

Medical & biological engineering & computing, 2020-05, Vol.58 (5), p.1031-1045

2020

Volltextzugriff (PDF)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Frontiers in immunology, 2023-06, Vol.14, p.1187332-1187332

2023

Volltextzugriff (PDF)

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

Frontiers in immunology, 2022-04, Vol.13, p.850226-850226

2022

Volltextzugriff (PDF)

A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma

International journal of molecular sciences, 2021-04, Vol.22 (9), p.4322

2021

Volltextzugriff (PDF)

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy

Cells (Basel, Switzerland), 2021-03, Vol.10 (3), p.607

2021

Volltextzugriff (PDF)

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

Cancers, 2021-05, Vol.13 (9), p.2225

2021

Volltextzugriff (PDF)

Vasculogenic mimicry structures in melanoma support the recruitment of monocytes

Oncoimmunology, 2022-12, Vol.11 (1), p.2043673-2043673

2022

Volltextzugriff (PDF)

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

Molecular oncology, 2022-03, Vol.16 (6), p.1221-1240

2022

Volltextzugriff (PDF)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e005187

2022

Volltextzugriff (PDF)

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma

PloS one, 2012-10, Vol.7 (10), p.e48424-e48424

2012

Volltextzugriff (PDF)

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Clinical & translational immunology, 2019, Vol.8 (5), p.e1050-n/a

2019

Volltextzugriff (PDF)

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy

Clinical & translational immunology, 2020, Vol.9 (10), p.e1191-n/a

2020

Volltextzugriff (PDF)

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

Immunology and cell biology, 2024-08, Vol.102 (7), p.535-537

2024

Volltextzugriff (PDF)

Effective γδ T‐cell clinical therapies: current limitations and future perspectives for cancer immunotherapy

Clinical & translational immunology, 2024, Vol.13 (2), p.e1492-n/a

2024

Volltextzugriff (PDF)

A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties

Oncotarget, 2015-03, Vol.6 (9), p.7065-7083

2015

Volltextzugriff (PDF)

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009486

2024

Volltextzugriff (PDF)

Cutaneous CXCL14 Targets Blood Precursors to Epidermal Niches for Langerhans Cell Differentiation

Immunity (Cambridge, Mass.), 2005-09, Vol.23 (3), p.331-342

2005

Volltextzugriff (PDF)

Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

Clinical cancer research, 2009-03, Vol.15 (6), p.2166-2173

2009

Volltextzugriff (PDF)

Desmoglein-2 as a cancer modulator: friend or foe?

Frontiers in oncology, 2023, Vol.13, p.1327478-1327478

2023

Volltextzugriff (PDF)

Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

Clinical cancer research, 2009-04, Vol.15 (7), p.2507-2513

2009

Volltextzugriff (PDF)

Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma

Clinical & translational immunology, 2024-01, Vol.13 (7), p.e1519-n/a

2024

Volltextzugriff (PDF)

Clinical chimeric antigen receptor T‐cell therapy: a new and promising treatment modality for glioblastoma

Clinical & translational immunology, 2021, Vol.10 (8), p.n/a

2021

Volltextzugriff (PDF)

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments

Biochemical Society transactions, 2019-04, Vol.47 (2), p.625-638

2019

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(110)
Japanisch
(11)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma

CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix

DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

Vasculogenic mimicry structures in melanoma support the recruitment of monocytes

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

Effective γδ T‐cell clinical therapies: current limitations and future perspectives for cancer immunotherapy

A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Cutaneous CXCL14 Targets Blood Precursors to Epidermal Niches for Langerhans Cell Differentiation

Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

Desmoglein-2 as a cancer modulator: friend or foe?

Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma

Clinical chimeric antigen receptor T‐cell therapy: a new and promising treatment modality for glioblastoma

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments

Suchergebnisse filtern